<DOC>
	<DOCNO>NCT01381848</DOCNO>
	<brief_summary>The purpose study measure drug level doripenem blood sample collect administration doripenem infant less 12 week age hospitalize document , presume , risk bacterial infection ( ) undergo treatment intravenous ( i.v . ) antibiotic . Safety tolerability also assess .</brief_summary>
	<brief_title>A Study Doripenem Infants Less Than 12 Weeks Age</brief_title>
	<detailed_description>This multicenter , open-label ( identity treatment know patient 's parent/legal guardian/caregiver study staff ) pharmacokinetic study ( study observe drug absorb distribute within body ) measure drug level doripenem hospitalize medically stable infant ( term preterm ) , &lt; 12 week chronological age ( CA ) ( age since time birth ) document , presume , risk bacterial infection ( ) undergo treatment intravenous ( i.v . ) ( administer vein ) antibiotic . Doripenem administer alone time first dose nonstudy antibiotic administer patient . Doripenem use study treat infection replace patient 's prescribe antibiotic ( ) . The duration study 9 day patient . Patients ' safety monitor throughout study safety committee review safety information least month every 8 patient enrol dosed . Safety evaluation include , limited , adverse event , clinical laboratory test , vital sign . A single dose study drug ( doripenem ) administer patient hospitalized setting . Patients &lt; 8 week CA receive 5 mg/kg doripenem 1-hour i.v . infusion , patient &gt; =8 week CA receive 8 mg/kg doripenem 1-hour infusion . Study drug administerd patient alone time first dose nonstudy antibiotic administer patient .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Must hospitalize , medically stable , without acute decline physical condition inestigator 's judgement Documented , presume , risk bacterial infection ( ) undergo treatment i.v . antibiotic Patient 's weight ( kg ) must within 5th 95th percentile inclusive age Parent patient 's legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing allow infant participate study Clinically significant abnormal value hematology clinical chemistry screen deem appropriate investigator Clinically significant abnormal physical examination vital sign screen , deem appropriate investigator Patients , investigator 's judgment , compromise renal ( kidney ) function include renal failure History clinically significant allergy medication , especially know hypersensitivity intolerance carbapenems , penicillin , beta lactam antibiotic Known allergy heparin history heparininduced thrombocytopenia , indwell cannula ( e.g. , heparin lock ) central line use Patients concomitantly treat received imipenem/cilastin within 48 hour study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Doripenem</keyword>
	<keyword>DORIPED1003</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Infection</keyword>
	<keyword>Colonization</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>